Literature DB >> 2831901

Stabilizing basic fibroblast growth factor using protein engineering.

M Seno1, R Sasada, M Iwane, K Sudo, T Kurokawa, K Ito, K Igarashi.   

Abstract

Using site directed mutagenesis, each of the four cysteines present at amino acid residues 26, 70, 88, and 93 of the mature protein of human basic fibroblast growth factor (bFGF) was individually changed to serine. The biological activity and heparin binding ability was retained when the serine was substituted for the cysteine residue at either 70 or 88 of the bFGF protein. This finding indicates that the cysteines at these positions are not essential for expressing biological activity. The substitution of the residues at these positions, especially at position 88, reduced the heterogeneity recognized as several peaks of bFGF eluted from a heparin affinity column, even after oxidation with hydrogen peroxide, suggesting that the cysteines at these positions are exposed to the surface of the molecule to form disulfide bonds that induce heterologous conformations. Furthermore, under acidic conditions, these modified bFGFs are revealed to be more stable in maintaining their activity. These facts suggest that this protein has been successfully modified by protein engineering.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831901     DOI: 10.1016/s0006-291x(88)80337-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing.

Authors:  J Folkman; S Szabo; M Stovroff; P McNeil; W Li; Y Shing
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

2.  Three-dimensional structure of human basic fibroblast growth factor.

Authors:  A E Eriksson; L S Cousens; L H Weaver; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta.

Authors:  J D Zhang; L S Cousens; P J Barr; S R Sprang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Formulation design of acidic fibroblast growth factor.

Authors:  P K Tsai; D B Volkin; J M Dabora; K C Thompson; M W Bruner; J O Gress; B Matuszewska; M Keogan; J V Bondi; C R Middaugh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

5.  Scintigraphic detection of xenografted tumors producing human basic fibroblast growth factor.

Authors:  H Kobayashi; H Sakahara; M Hosono; M Shirato; J Konishi; J A Takahashi; Y Oda; H Kikuchi; K Endo; Y Kozai
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

6.  Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration.

Authors:  M A Hull; D J Cullen; N Hudson; C J Hawkey
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

7.  Expression of basic fibroblast growth factor in hyperplastic parathyroid glands from patients with multiple endocrine neoplasia type I.

Authors:  M Komatsu; S Tsuchiya; I Matsuyama; S Kaneko; Y Suzuki; N Ito; N Hanamura; T Seki; S Kobayashi; T Kuroda
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

8.  Susceptibility towards intramolecular disulphide-bond formation affects conformational stability and folding of human basic fibroblast growth factor.

Authors:  D Estapé; J van den Heuvel; U Rinas
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

9.  Effect of basic fibroblast growth factor on reinnervation of gastric microvessels. Possible relevance to ulcer recurrence.

Authors:  M Nakamura; M Oda; J Inoue; T Ito; Y Akiba; M Kitajima; M Tsuchiya; H Ishii
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

10.  Effects of sterilization on an extracellular matrix scaffold: part I. Composition and matrix architecture.

Authors:  Jason Hodde; Abram Janis; David Ernst; David Zopf; Debra Sherman; Chad Johnson
Journal:  J Mater Sci Mater Med       Date:  2007-04       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.